More recently, other treatments such as lenvatinib (an inhibitor of vascular endothelial growth factor (VEGF) receptors 1–3, fibroblast growth factor (FGF) receptors 1–4, and platelet-derived growth factor (PDGF) receptor α) have proven noninferiority in terms of OS in treated vs. untreated advanced HCC patients [45]. The gene discussed is VEGFA; the disease is hepatocellular carcinoma.